Prne
August 16th, 2009
LEIDEN, The Netherlands - A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide. A total budget of nearly 3.6 million euros has been allocated over the next 4 years, to develop effective drugs for these diseases. The consortium includes IOTA Pharmaceuticals, Mercachem, Nycomed, the Drugs for Neglected Diseases initiative, the Royal Tropical Institute, the University of Bern, the VU University Amsterdam and TI Pharma.
Rob Leurs (VU University Amsterdam), the project’s principal investigator, comments: “African sleeping sickness and Leishmaniasis are diseases caused by parasites. Both diseases are prominent on the World Health Organization’s list of neglected tropical diseases for which no effective medication is available.” The new consortium will target parasite-specific phosphodiesterase to develop and screen drug candidates for clinical evaluation and the treatment of both diseases. Leurs continues: “This new project combines the knowledge and experience of leading European laboratories and promises to make a major contribution to the treatment of neglected tropical diseases.”
African sleeping sickness
Recent WHO estimates indicate that approximately 60 million people are at risk of contracting the African sleeping sickness (also called human African trypanosomiasis) with an estimated 50,000 to 70,000 new cases occurring each year. The disease appears in 36 countries in sub-Saharan Africa and is endemic in south-east Uganda and western Kenya, killing more than 40,000 Africans each year. The African sleeping sickness parasite, most commonly Trypanosoma brucei, is transmitted to humans by tsetse fly bites.
Leishmaniasis
Leishmaniasis is found in many tropical and sub-tropical countries, in settings as diverse as the rainforests in Central and South America to deserts in Asia and the Middle East. 350 million people are at risk of developing the disease, with as many as 12 million people worldwide being infected, and 1.5-2 million new cases occurring each year. Leishmaniasis presents in cutaneous, visceral and mucosal forms, with the visceral form of the disease alone having an estimated incidence of 500,000 new cases each year, and causing 60,000 deaths. Many different Leishmania species are implicated in the disease, which is transmitted by sand flies.
Neglected diseases framework
Neglected diseases such as African Sleeping Sickness, Leishmaniasis and Malaria, represent a major economic burden on developing countries. Within its project portfolio, TI Pharma is seeking to develop solutions to these diseases, mobilizing public and private partners in multilateral consortia - bringing together a wide range of competences and resources. This new project on phosphodiesterase is TI Pharma’s sixth initiative in neglected diseases. Other projects focus on:
- the development of a protective malaria vaccine; - a ‘proof of concept’ vaccine for Chikungunya; - an effective HIV therapy; - drug formulations that can resist tropical conditions without refrigeration for both oxytocin and insulin as well as vaccines for hepatitis B and influenza; - fixed dose combinations of formulations for drugs, applicable to combination therapies in many diseases, including neglected diseases.
For more information on TI Pharma’s projects on neglected diseases, please visit www.tipharma.com/research/priority-medicines/neglected-diseases
Source: TI Pharma
For more information, please contact Ingeborg van der Heijden: +31-71-3322036.
Filed under Business, Clinical Trials / Medical Discoveries, Health, Health Care / Hospitals, New Products / Services, Pharmaceuticals | Tags: Africa, kenya, Leiden, Netherlands, Switzerland, TI Pharma, Uganda | Comment Below
Related Press Releases MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014August 31st, 2009 WILMINGTON, Delaware - According to a new market research report, 'Global Autoimmune Treatment Market (2009-2014)', published by MarketsandMarkets ( www.marketsandmarkets.com), the global autoimmune treatment market is expected to be worth US$68.81 billion by 2014, with an estimated CAGR of 12.7% from 2009 to 2014. The North American market is expected to account for nearly 42% of the total revenues. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug PlatformAugust 23rd, 2009 CAMBRIDGE, Massachusetts -
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic DisordersAugust 23rd, 2009 HOERSHOLM, Denmark -
- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders
- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery
- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders. (Logo: www.newscom.com/cgi-bin/prnh/20090420/344344 )
The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New ProjectsJuly 5th, 2009 LEIDEN, The Netherlands - Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget of nearly 6 million euros. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory DiseasesJune 29th, 2009 SAN DIEGO -
- Results Demonstrate Positive Proof of Mechanism
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research ConferenceJune 14th, 2009 SAN DIEGO - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona. Merck Serono Committed to Investing in Innovation in the Fertility AreaMay 17th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, confirms its commitment to investing in the therapeutic area of fertility, after Merck KGaA informed earlier today the Oslo Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in Assisted Reproductive Technologies (ART), as the required share threshold was not reached in the set timeframe. "Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments," said Dr. Consumers Rank Wireless Power Charging in Top 20% of Lifestyle Demands According to Market ResearchApril 26th, 2009 HONG KONG - Wireless Power Consortium pursues universal wireless power to fulfill consumer need
Citing syndicated and proprietary international market research from sources including Ipsos Vantis, AcuPOLL(R), and Frost & Sullivan, the Wireless Power Consortium (the Consortium) continues to drive toward an interoperable wireless power standard for consumer devices requiring up to 5 Watts of power. The studies, conducted in 2007 and 2008, focused on teens, adults, and seniors from around the world and illustrate a very strong demand for a power solution that converges with the growing international wireless lifestyle. Comic Relief Invests GBP6.3m to Tackle MalariaApril 22nd, 2009 LONDON - Just days ahead of World Malaria Day 2009 Comic Relief has awarded GBP6.3m in funding to Malaria Consortium and the Global Fund to help protect over 1m people in Africa from malaria. Comic Relief selected Malaria Consortium and the Global Fund to Fight AIDS, Tuberculosis and Malaria as recipients of these awards to ensure that long-lasting insecticide treated bed nets (LLINs) and life-saving drugs reach malaria-affected communities quickly. Dutch Consortium Builds Registry Framework for Care of Rare DiseasesApril 5th, 2009 LEIDEN, The Netherlands - The Dutch Orphan Disease Registry Consortium is set up in order to build a disease registry framework to collect information on rare diseases, encourage drug development and optimize patient care. The consortium focuses on inborn errors of metabolism as target group of diseases.
Related News G8 assesses impact of global economic crisisJune 11th, 2009 ROME - The impact of the global economic crisis on poorer nations and ways to promote sustainable development strategies topped the agenda Thursday at the first ever meeting of ministers responsible for international cooperation from the Group of Eight (G8) industrialised nations. Special attention would be devoted to difficulties being experienced by countries in Africa, according to the programme of the two-day meeting in Rome. Scientists map epidemic trigger zonesJanuary 4th, 2009 SYDNEY - Scientists have identified and mapped potential zones that can trigger deadly outbreak of plagues and epidemics, with devastating consequences. 'A study has revealed a number of global hot-spots where new and unknown diseases are most likely to erupt - and it turns out that one of the hottest is spread in an arc to Australia's north,' warned Stephen Prowse. Tropical Storm Danny: NHC UpdateAugust 26th, 2009 Satellite pictures indicate that the area of disturbed weather east of The Bahamas has developed a well-defined low level circulation - Tropical Storm Danny. Tropical storm force winds are occurring north and north-east of the center and the structureas resembles more like a tropical cyclone according to cyclone phase analysis from Florida State University. Russia, Venezuela sign package of oil dealsSeptember 10th, 2009 MOSCOW - Russia and Venezuela signed Thursday a package of deals, including one to develop the Latin American country's Orinoco oil belt, with estimated reserves of 235 billion barrels of heavy oil. Venezuela's PdVSA state oil firm and a consortium of major Russian producers signed a memorandum of understanding on cooperation in Orinoco, and a separate memo on establishing a joint venture to develop the Junin-6 field. Forecasters: Tropical depression forms in Pacific, likely to strengthen into tropical stormAugust 24th, 2009 Tropical depression forms far out in PacificMIAMI — A tropical depression has formed far out over the Pacific Ocean and forecasters say it could become a tropical storm. According to the National Hurricane Center in Miami, the depression has maximum sustained winds near 35 mph (55 kph) but is expected to strengthen. New tropical depression forms in the Pacific Ocean, expected to become tropical stormSeptember 22nd, 2009 Tropical depression forms in the PacificMIAMI — A tropical depression has formed out in the Pacific Ocean. The depression has maximum sustained winds near 35 mph (55 kph) Tuesday night. New tropical depression forms in Atlantic, Tropical Storm Felicia swirls in PacificAugust 11th, 2009 New tropical depression forms in the AtlanticMIAMI — A new tropical depression has formed in the Atlantic while Tropical Storm Felicia continues to move across the Pacific. The new tropical depression is only the second of the Atlantic hurricane season and has maximum sustained winds near 30 mph. Genes behind ageing process identifiedMay 26th, 2009 LONDON - British scientists have identified genes that control the ageing process. The finding could lead to new drugs to prevent illnesses from heart disease to Alzheimer's. Exposure to sunlight can cause autoimmune diseases in womenJuly 31st, 2009 WASHINGTON - A new research has cited that ultraviolet (UV) radiation from sunlight can instigate certain autoimmune diseases, particularly in women. The study, led by Dr. Tropical depression forms in Eastern Pacific; forecasters say could become tropical stormAugust 4th, 2009 Tropical depression forms in Eastern PacificMIAMI — The National Hurricane Center says a tropical depression has formed in the Eastern Pacific and is expected to intensify into a tropical storm within a day. Forecasters say the depression is the seventh of the 2009 Eastern Pacific hurricane season.
|
|
